Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Market Cap	281.45M
Revenue (ttm)	55.93M
Net Income (ttm)	23.65M
Shares Out	19.96M
EPS (ttm)	1.11
PE Ratio	12.68
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	138,970
Average Volume	203,365
Open	14.00
Previous Close	14.10
Day's Range	13.68 - 14.58
52-Week Range	5.20 - 16.00
Beta	0.75
RSI	61.87
Earnings Date	Dec 18, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: NWRN

Financial Performance

Financial numbers in EUR